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Sepsis is a major cause of mortality and morbidity in intensive care units. Organ dysfunction is triggered by
inflammatory insults and tissue hypoperfusion. The brain plays a pivotal role in sepsis, acting as both a mediator of
the immune response and a target for the pathologic process. The measurement of brain dysfunction is difficult
because there are no specific biomarkers of neuronal injury, and bedside evaluation of cognitive performance is
difficult in an intensive care unit. Although sepsis-associated encephalopathy was described decades ago, it has only
recently been subjected to scientific scrutiny and is not yet completely understood. The pathophysiology of sepsis-
associated encephalopathy involves direct cellular damage to the brain, mitochondrial and endothelial dysfunction
and disturbances in neurotransmission. This review describes the most recent findings in the pathophysiology,
diagnosis, and management of sepsis-associated encephalopathy and focuses on its many presentations.
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INTRODUCTION
The doctors said that it was puerperal fever and that it was
ninety-nine chances in a hundred it would end in death. The whole
day long there was fever, delirium, and unconsciousness. At
midnight the patient lay without consciousness, and almost
without pulse.
The end was expected every minute.
Leo Tolstoy’s Anna Karenina
Sepsis syndromes, which account for up to 50% of deaths
in intensive care units (ICUs), are associated with high
morbidity and mortality rates.
1 Early recognition and
appropriate therapy of sepsis could alter the impending
cascade of hypoperfusion, inflammation and organ dys-
function, thereby reducing the mortality rate.
1 Most
proposed sepsis treatments focus on prompt antibiotic
therapy, control of the infectious source, and global
hemodynamic goals.
2 Organ dysfunction is often diagnosed
using laboratory parameters rather than on clinical para-
meters.
3 Brain dysfunction, or sepsis-associated encephalo-
pathy (SAE), has been neglected until recently because there
are no precise, well-established clinical or biological
markers of damage to the brain during sepsis.
4
This narrative review describes the most recent findings
in the pathophysiology and diagnosis of SAE, as well as
advances in the management of patients with SAE. Because
much of the scientific knowledge regarding SAE is relatively
new, this comprehensive review covers most of the
physiological and clinical aspects of this condition. A
directed, non-systematic search of the medical literature
using Pubmed, OVID, and Google Scholar was performed to
identify research and review articles involving the patho-
physiology, diagnosis, and treatment of SAE. The most
relevant studies were selected in the following order:
a. clinical trials.
b. animal models of clinical disease.
c. laboratory studies reporting relevant findings on
SAE pathophysiology.
Definitions, Historical Aspects, and Incidence
Although delirium is a major component of the clinical
presentation of SAE, the two conditions are not synon-
ymous. SAE is defined as any brain dysfunction related to
septic illness. Delirium is a fluctuating disorder of con-
sciousness that is associated with a change in cognition or
perceptual disturbance; it can be caused by any general
medical condition.
5 SAE is one of many causes of delirium,
but delirium is not the only clinical presentation of SAE.
SAE is not a newly recognized disorder. In 1903, Dr.
Kingsmill Jones defined febrile delirium as a prejudice of
the brain’s higher functions triggered by a febrile infectious
disease that could occur during or after fever.
6 He asserted
that post-febrile insanity was a rare condition that was not
‘‘merely due to the wasting and exhaustion caused by
fever.’’ According to Dr. Jones’ theory, the condition could
not be cured with rest and good nutrition because ‘‘the
specific poison of the fever must be a factor in causing post-
febrile insanity.’’ Dr. Jones was the first author to
hypothesize that the same factor that caused fever could
be related to brain dysfunction.
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1825Physicians are now aware that SAE is a common
condition
4,7 that can significantly impact patient outcomes.
Altered mental status is present in up to 23% of patients
with sepsis.
7 Mental dysfunction may even precede the
cardinal findings of sepsis.
8 When present, SAE is asso-
ciated with a poor prognosis.
7 In the classic report by
Sprung et al.,
7 the mortality rate of septic patients with
altered mental status was 49% compared with a rate of 26%
in septic patients with no neurological symptoms. Eidelman
et al.
9 reported that the severity of neurological symptoms
secondary to encephalopathy in patients in the ICU, as
assessed by the Glasgow Coma Scale, was correlated to
prognosis, with a mortality rate of up to 63% in patients who
presented with Glasgow Coma Scale scores between 3 and
8. In a recent epidemiological multicentric study with 497
patients, including 76 septic patients, the overall prevalence
of delirium was 32.3%.
10 ICU and hospital mortalities were
increased in patients with delirium. No studies to date have
evaluated the actual incidence of the various types of SAE.
Therefore, the actual incidence of neurological changes due
to sepsis and its associated mortality might be under-
estimated.
Pathophysiology
The complete pathophysiology of SAE is unknown,
11 but
several mechanisms have been proposed. SAE appears to
involve direct cellular damage to the brain, mitochondrial and
endothelial dysfunction, neurotransmission disturbances and
derangements of calcium homeostasis in brain tissue.
12
Cerebral blood flow may also be affected.
13 Because the
evaluation of cerebral function during human sepsis is difficult,
much of the associated knowledge comes from laboratory
studies in animal models of sepsis. Figure 1 summarizes the
main mechanisms related to SAE pathogenesis.
Neurotransmission: Several neurotransmitters appear to be
related to SAE, including the cholinergic pathway
14 and the
expression of receptors for c-aminobutyric acid,
15 norepi-
nephrine, serotonin, and dopamine.
16
Han et al. associated the use of anticholinergic drugs with
symptoms of delirium.
14 Comim et al.
17 evaluated the role
of rivastigmine, a cholinesterase inhibitor, in the treatment
of memory impairment in rats following cecal ligation and
puncture (CLP). Rivastigmine improved performance in
an open-field memory test in animals evaluated 10 days
after CLP, suggesting that acetylcholine deficiency may be
prolonged.
In vivo measurement of neurotransmitters is difficult,
requiring lumbar puncture or the use of brain microdialy-
sis.
18 Pandharipande et al.
18 postulated that the serum
measurement of large neutral amino acids (LNAA) could
be related to delirium during critical illness because LNAAs
are predecessors of many neurotransmitters. Tryptophan
(Trp) is necessary for serotonin synthesis; phenylalanine
(Phe), together with Tyrosine (Tyr), is required for dopamine
and norepinephrine production. In fact, the relationship
between plasma Trp and total LNAA (Trp/LNAA ratio) and
between plasmaTyrandtotalLNAA(Tyr/LNAAratio)were
both statistically related to the diagnosis of brain dysfunction
during critical illness.
18
Reduced levels of branched-chain amino acids (BCAAs-
leucine, isoleucine and valine), a group of LNAA, could be
related to the increase in brain concentrations of aromatic
Figure 1 - Schematic representation of the main pathophysiological mechanisms of SAE. The inflammatory response is represented by
TNF-a induction, which increases BBB damage and the liberation of aquaporin 4 to cause brain edema. Mitochondrial dysfunction and
the reduction in oxidative phosphorylation efficiency (cytochrome c malfunction) may induce apoptosis and trigger brain injury. The
accumulation of false neurotransmitters may increase intracellular calcium content and contribute to encephalopathy. Cerebral
perfusion may be altered, rendering brain function more susceptible to injury. TNF-a: Tumor necrosis factor a. NO: nitric oxide. LNAA:
Large, neutral amino acids. BCAA: Branched-chain amino acids. SAE: sepsis-associated encephalopathy. BBB: blood-brain barrier.
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1826amino acids (AAA). BCAAs and AAA compete for the same
transporter in the blood-brain barrier (BBB).
19 If BCAA
levels are low, there will be an increase in brain uptake of
AAA and, theoretically, an increase in levels of neurotrans-
mitters associated with SAE.
Berg et al.
20 further explored the relationship between
BCAA and AAA in sepsis. After the infusion of E. coli
lipopolysaccharide (LPS) in 12 healthy individuals, the
plasma BCAA/AAA ratio declined, mainly because of
increases in serum concentrations of Phe and decreases in
concentrations of valine and isoleucine. Phe is potentially
neurotoxic and can generate false neurotransmitters.
21 This
study confirms that there is an important interplay between
BCAAs and AAA. However, no volunteers developed signs
or symptoms of SAE.
Supplementation with BCAAs has been suggested as a
therapeutic approach because of their decreased concentra-
tions during sepsis.
22 Freund et al.
22 demonstrated that
survivors of sepsis had higher levels of BCAAs than those
who eventually died, suggesting a more adequate energy
supply in the surviving patients. In a non-matched inter-
ventional group of five patients, the infusion of a parenteral
nutritional supplement that was rich in BCAAs reversed
SAE. However, randomized clinical trials that include the
treatment of SAE with BCAAs are lacking.
Mitochondrial dysfunction: The complex association
between mitochondrial dysfunction and target organ
damage in sepsis has been extensively reviewed.
23-25 The
roles of mitochondria reach far beyond energy production
and involve diverse metabolic pathways, including cell
death.
25 Sepsis is associated with mitochondrial dysfunc-
tion, which can have remarkable consequences for cells and
the health of the host. In brief, early sepsis is associated with
a decrease in mitochondrial ATP generation, which is likely
mediated by cytokines, reactive oxygen species (ROS), and
nitric oxide (NO),
23 suggesting an energy deficit that could
be related to tissue and organ damage. The mitochondria
might trigger cellular apoptosis later in the course of the
disease by releasing cytochrome c, for example.
25
Although necrosis and apoptosis are present in sepsis,
several concerns regarding tissue damage have been raised.
In most situations, organ function improves as sepsis is
treated, indicating a lack of massive or irreversible anatomic
tissue damage. Additionally, one study suggested that
apoptosis is a minor feature in the autopsies of septic
patients.
26 The mitochondria might be associated with an
adaptive suspended animation-like state
23 in which cells
either recover or undergo programmed cell death, depend-
ing on the magnitude of the offending event.
Cytochrome c oxidase may play an important role in
mitochondrial dysfunction,
23 and replacement therapy with
cytochrome c has been proposed as a possible treatment for
sepsis.
27 A recent study by d’A ´ vila et al.
28 evaluated
mitochondrial function in brain homogenates of septic mice
after CLP. The study showed a reduction in the efficiency of
oxidative phosphorylation in the mitochondria and reduced
levels of cytochrome c oxidase in the brain following CLP.
The mitochondria are also involved with mechanisms
related to neural apoptosis during sepsis, as illustrated by
Messaris et al.
29 An increase in Bax levels was found in
neuronal cells in early stages of sepsis after CLP in rats,
primarily in areas with more permissive BBBs, including the
hippocampus, choroid plexus, and Purkinje cells. The bax
gene is part of the bcl-2 gene family and is associated with
regulation of programmed cell death on various biological
scenarios.
29 Increased levels of Bax likely induce apoptosis
by releasing cytochrome c from the mitochondria into the
cell cytoplasm, although cytochrome c release was asso-
ciated with improved prognosis in this study. Therefore,
mitochondrial dysfunction may be related to both the
induction of neural cell apoptosis and an insufficient energy
supply.
Brain cell death: Until recently, it was uncertain whether
SAE is associated with irreversible brain lesions.
30 Critical
illness independently is associated with long-term cognitive
impairment (LTCI),
31 and a link between severe sepsis and
LTCI was recently established in a large cohort of patients.
32
Brain involvement in critical illnesses may be a trigger for
LTCI or a sign of poor prior brain reserves that is not
detectable by screening tests. Additionally, LTCI might be a
consequence of brain cell death.
33
Brain cell death occurs in SAE, as shown by elevated
S100b and neuron-specific enolase (NSE).
34 S100b is a
calcium-binding protein that is produced mainly by the
central nervous system and is released during neuronal or
glial injury. Because the normal BBB is impermeable to
S100b, elevated serum levels of S100b are a marker of
neuronal and BBB damage.
Controversy exists regarding the specificity of S100b and
NSE
35 in predicting brain injury. Increases in S100b levels in
critically ill patients without apparent brain damage have
been reported.
36 The increases in S100b were not correlated
with the severity of clinical encephalopathy in cases of
sepsis.
37 Therefore, elevations in S100b and NSE levels may
be related to critical illness per se or may be markers of
minor brain damage caused by inflammation and early
organ dysfunction that cannot be otherwise diagnosed.
Calcium homeostasis: An increase in intracellular calcium
levels is associated with sepsis-induced brain injury.
12 Zhan
et al. demonstrated that hippocampal intracellular calcium
levels were increased after CLP in rats.
12 This increase could
be related to ischemia, the presence of excitatory amino
acids or a direct effect of cytokines. Altered calcium levels
may alter neurotransmitter levels and impair learning,
memory and cognitive function in septic patients.
Endothelial and BBB dysfunction: Endothelial dysfunction
plays an important role in SAE pathogenesis. Under normal
conditions, the BBB protects the brain from a number of
insults and creates a tightly regulated microenvironment for
neural cells. Important functions of the BBB include the
regulation of capillary blood flow and the protection of the
brain from circulating noxious substances. The integrity of
the BBB is maintained by interactions between astrocytic
foot processes, pericytes, and endothelial cells.
13 During
sepsis, breakdown of the BBB facilitates the passage of
neurotoxic factors. Disruption of tight junctions in endotox-
emia and detachment of brain pericytes in the hippocampus
have been reported.
38 Both mechanisms could account for
brain edema and BBB dysfunction in patients with SAE. In
vitro exposure of mouse brain endothelial cells to the plasma
of septic animals induces the production of ROS and NO,
which may be related to SAE.
39
Inflammation is related to increased BBB permeability to
cytokines
40 and the expression of adhesion molecules. The
activation of leukocytes during sepsis causes these cells to
adhere to blood vessels and pass to the tissues in a process
mediated by adhesion molecules. There is increased expres-
sion of intercellular adhesion molecule 1 (ICAM-1) during
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41 Monocytes that adhere to the
endothelium and are transferred to the surrounding tissues
can proliferate and expand the population of perivascular
macrophages, contributing to cerebral inflammation.
13
In addition to experimental models, BBB dysfunction has
been demonstrated in septic patients by brain magnetic
resonance imaging (MRI).
42 BBB breakdown is more
frequent around the Virchow-Robin spaces or is diffuse
throughout the white matter and posterior lobes. These
findings are consistent with posterior reversible encephalo-
pathy syndrome, which is discussed later.
4
Inflammatory mediators and complement system: Of the many
inflammatory mediators that are involved in SAE, TNF-a
appears to be one of the most significant.
13,40,43 Alexander et
al.
43 evaluated the role of brain TNF receptor-1 (TNFR1) in
LPS-treated mice. TNF-a induces neutrophil infiltration of
the brain tissue, neuronal cell apoptosis, and brain edema
(likely by inducing the expression of aquaporin 4). Mice that
are knockouts for the TNFR1 gene showed reduced
apoptosis and brain edema.
Jacob et al.
44 highlighted the effects of the complement
cascade during SAE in LPS-treated mice. Genetically
modified mice that overexpressed CR1-related y (Crry-tg),
a potent complement inhibitor, had an attenuated inflam-
matory response, with less apoptosis and cerebral edema,
after LPS infusion. In addition, inhibition of complement
factor C5a in a CLP model was associated with improved
BBB function.
45
Cerebral blood flow: Brain ischemia has been described in
the autopsy findings of patients following death from septic
shock, suggesting that there may be alterations in cerebral
blood flow during SAE.
46-48 Hypotension and low cardiac
output could be related to these findings. Because most
available data have been obtained from similar autopsy
studies, it is uncertain whether cerebral blood flow reduc-
tion is universally present in SAE or is only found in
extremely ill patients who eventually die. A myocardial
depression in septic patients could be linked to insufficient
blood flow to the organs, including the brain.
47 Earlier
reports also suggest that blood flow may be reduced in the
brains of septic patients.
49
Pfister et al. evaluated cerebral blood flow using
transcranial Doppler in a small series of patients.
50 There
was no association between SAE and altered brain perfusion
that was reported in the middle cerebral artery. However,
the autoregulation of blood flow was disturbed in patients
with SAE, suggesting that the septic brain is more
susceptible to variations in mean arterial pressure.
Other factors that may influence cerebral perfusion in
sepsis have recently been reviewed.
47 Burkhart et al.
47
proposed that cerebral perfusion in sepsis is related to both
macro- and micro-hemodynamic features. Concerning micro-
circulation, flow was dependent on the function of the BBB
and the local production of NO and ROS. Taccone et al.
explored microcirculation in the septic brain in a sheep
model.
51 Using video microscopy, the authors showed a
profound impairment of cerebral microcirculation in sepsis,
whichwascharacterizedbyareductioninfunctionalcapillary
density and the proportion of perfused capillaries. These
changes were unrelated to the systemic hemodynamic status.
Lessons from Neuropathology
Neuropathology could supply clues to our understanding
of SAE.
42,46,48 In a series of 23 patients who died from septic
shock,allpatientshadsomedegreeofbrainischemia.
46Other
reported findings included multifocal necrotizing leukoen-
cephalopathy (9%), micro-abscesses (9%), hemorrhages
(26%), and hypercoagulability (9%). Another series from the
same group evaluated brain imaging resonance in SAE and
performed autopsies in selected cases
42 with varying results.
The findings suggested a predominance of white matter
lesions, with swelling and dilation of the perivascular spaces
and occasional Periodic acid-Schiff stain (PAS) positive fibrin
exudates. There were no signs of direct brain involvement,
such as micro-abscesses.
Janz et al.
48 evaluated the autopsy findings of seven
patients with delirium who eventually died. Hypoxic
ischemic injury, which was noted in six patients, was the
most common finding. Hippocampal injury was present in
five patients. Patients with hippocampal lesions spent an
average of 5.8 days in delirium and received an average of
2.2 different analgesics and/or sedatives to control their
symptoms. As a result, the authors hypothesized that there
is a positive correlation between hippocampal injury and
symptoms of delirium.
These findings suggest that white matter and the
hippocampus are involved in SAE pathogenesis. This
conclusion corroborates the concept that BBB damage is
one of the key mechanisms involved in SAE. Hippocampal
involvement may be related to the clinical picture of
delirium.
Clinical Findings and Diagnosis
It must be clearly stated that SAE is a diagnosis based on
exclusion.
8 Diagnosing SAE is challenging, especially in
chronic critical illnesses. Several medical conditions must be
excluded before a diagnosis of SAE can be made, including
drug use, central nervous system disorders, and electrolyte
disturbances. Most patients in the ICU have multiple risk
factors for brain dysfunction. Consequently, the brain
dysfunction associated with critical illness is often multi-
factorial.
8,52
SAE could present with symptoms that range from a few
clinical findings to a coma and could entirely bypass the
stage of delirium (Figure 2).
8,52-54 Therefore, the diagnosis of
SAE should not be made using the DSM IV
5 criteria for
delirium or the CAM-ICU questionnaire.
55 To date, no tool
is capable of diagnosing the full spectrum of SAE.
Altered consciousness is often a cardinal finding of SAE.
54
Focal motor deficits and seizures have been reported
56,57 but
are not common and should prompt a detailed investigation
with brain imaging and possibly lumbar puncture. Ordinary
causes of coma should also be evaluated.
Electroencephalography (EEG) has been proposed as an
important tool in the evaluation of SAE.
58,59 Young et al.
58
studied 69 septic patients, 49 of whom had some degree of
encephalopathy that was categorized as either mild or
severe. EEG patterns were classified into five categories:
normal, theta, delta, triphasic waves (TW), or suppression.
The TW and suppression categories were present only in
patients with severe disease. Theta waves were more
common in the mild forms of encephalopathy. The EEG
pattern was associated with mortality, but the limited
number of patients impeded further analysis. However,
none of the EEG findings were pathognomonic. EEG may be
useful in aiding the diagnosis of SAE because it can exclude
non-convulsive status epilepticus.
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1828Brain imaging findings may also be remarkable in patients
with SAE.
42,60,61 Sharshar et al. performed brain MRI
evaluations in nine critically ill septic patients.
42 Five of these
patients had white matter lesions (leukoencephalopathy) that
were characterized by hyperintensity on fluid-attenuated
inversion recovery (FLAIR) images and predominated
around enlarged perivascular spaces, which are likely related
to damage to the BBB. The severity of these lesions was
correlated to neurologic prognosis, as evaluated by the
Glasgow Outcome Scale.
Posterior reversible encephalopathy (PRE) may also be
linked to sepsis and infection.
62 In a study of 106 patients
with PRE, 23.6% had infection or sepsis/septic shock. The
clinical symptoms included altered mental status, seizures
and visual disturbances. PRE was not an early finding, as it
occurred up to 30 days after infection.
Brain imaging may aid in the diagnosis of SAE and may
exclude other causes of neurologic deterioration. Larger
case series are necessary to confirm the association between
white matter lesions and outcome.
Treating SAE
Treating and diagnosing SAE are equally challenging
tasks. Most treatment schemes are geared toward treating
the symptoms of delirium. None of the therapies that aim to
treat the pathophysiological mechanisms of SAE have been
proven effective in humans.
The use of anti-C5a antibody reduces BBB damage in a
CLP model
45 in rats, and C5a or C5aR blockade apparently
improves mortality in experimental studies.
63 The use of
drotrecogin alpha has been suggested to reduce neural
damage in human sepsis, as evaluated by serum measure-
ments of S100b.
64 However, it is unclear whether S100b is an
actual marker of brain injury. Because the study reported no
clinical endpoints, it is not advisable to advocate the use of
drotrecogin in the treatment of SAE.
Sedatives are often used in the intensive care unit, and the
use of benzodiazepines is related to the increased incidence
of brain dysfunction, as assessed by symptoms of delirium.
65
Dexmedetomidine, an alpha-2 agonist, has been associated
with less delirium than continuous lorazepam and mid-
azolam in critically ill patients (the MENDS trial).
65
Pandharipande et al. performed an a priori analysis of septic
patients,
66 including 63 patients that were administered
either lorazepam (32 patients) or dexmedetomidine (31
patients). Of the two groups, patients who received dexme-
detomidine had more delirium/coma-free days (3.2 days;
95% IC 1.1-4.9) and a lower 28-day mortality rate (hazard
ratio 0.3; IC 0.1-0.9). This study had several limitations,
including possible randomization issues due to the nature of
thesubgroup analysis anda small sample size, which made it
vulnerable to type II error. The results of the study could be
related to the beneficial effects of dexmedetomidine or the
hazardous effects of benzodiazepines. The possible favorable
effects of dexmedetomidine include the inhibition of apop-
tosis and reductions in the sepsis-associated inflammatory
response.
66 In the brain, dexmedetomidine has been shown
to decrease apoptosis by binding to a2-receptors,
67 which
may explain the reduction in symptoms of delirium in septic
individuals. Until additional evidence is available, dexme-
detomidine is preferredover benzodiazepines when sedation
is necessary for patients with SAE.
CONCLUSION
SAE is a multifaceted syndrome with serious effects on
patient morbidity and mortality. Its pathophysiology is
Figure 2 - Timeline of sepsis-associated encephalopathy (SAE). Although SAE may precede other symptoms of sepsis, a diagnosis is
usually missing until mixed encephalopathy becomes overt. Outcomes are variable and may be related to the degree of
encephalopathy and the occurrence of prior neurological disorders.
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1829complex and involves hemodynamic and inflammatory
features that are not completely understood. Therapy
choices are limited and are mainly based on symptom
control. Although therapy with antipsychotics is the
mainstay of treatment for symptomatic patients for
extended periods of time, there are limited data regarding
the efficacy and safety of these drugs when administered to
septic patients.
Much attention has been paid to symptoms of delirium.
The other forms of SAE, including PRE and leukoencepha-
lopathy, have not been thoroughly studied. Furthermore,
little is known about the natural history of the disease and
the actual impact on quality of life after a critical illness. SAE
should not be regarded as an acute reversible state. The
brain may be affected in sepsis, similar to any other organ,
but with many unique effects. Therefore, efforts should be
made to understand the multiple clinical presentations and
pathophysiology of SAE to target therapies toward the
mechanistic pathways of the disorder rather than to merely
control the symptoms of SAE.
REFERENCES
1. Martin GS, Mannino DM, Eaton S, Moss M. The Epidemiology Of
Sepsis In The United States From 1979 Through 2000. N Engl J Med.
2003;348:1546-54, doi: 10.1056/NEJMoa022139.
2. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al.
Surviving Sepsis Campaign: International Guidelines For Management
Of Severe Sepsis And Septic Shock: 2008. Crit Care Med. 2008;36:296-327,
doi: 10.1097/01.CCM.0000298158.12101.41.
3. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H,
et al. The SOFA (Sepsis-Related Organ Failure Assessment) Score To
Describe Organ Dysfunction/Failure. On Behalf Of The Working Group
On Sepsis-Related Problems Of The European Society Of Intensive Care
Medicine. Intensive Care Med. 1996;22:707-10, doi: 10.1007/BF01709751.
4. Iacobone E, Bailly-Salin J, Polito A, Friedman D, Stevens RD, Sharshar T.
Sepsis-Associated Encephalopathy And Its Differential Diagnosis.Crit Care
Med. 2009;37(10 Suppl):S331-S336, doi: 10.1097/CCM.0b013e3181b6ed58.
5. American Psychiatric Association. Diagnostic And Statistical Manual Of
Mental Disorders. 4th Ed. 2000.
6. Jones K. Delirium In Febrile Conditions. Dublin Journal Of Medical
Science. 1903;115:420-22.
7. SprungCL, Peduzzi PN, ShatneyCH, Schein RM, Wilson MF, SheagrenJN,
et al. Impact Of Encephalopathy On Mortality In The Sepsis Syndrome. The
Veterans Administration Systemic Sepsis Cooperative Study Group. Crit
Care Med. 1990;18:801-6, doi: 10.1097/00003246-199008000-00001.
8. Ebersoldt M, Sharshar T, Annane D. Sepsis-Associated Delirium.
Intensive Care Med. 2007;33:941-50, doi: 10.1007/s00134-007-0622-2.
9. Eidelman LA, Putterman D, Putterman C, Sprung CL. The Spectrum Of
Septic Encephalopathy. Definitions, Etiologies, And Mortalities. JAMA.
1996;14;275:470-3, doi: 10.1001/jama.275.6.470.
10. Salluh JI, Soares M, Teles JM, Ceraso D, Raimondi N, Nava VS, et al.
Delirium Epidemiology In Critical Care (DECCA): An International
Study. Crit Care. 2010;14:R210.
11. Flierl MA, Rittirsch D, Huber-Lang MS, Stahel PF. Pathophysiology Of
Septic Encephalopathy - An Unsolved Puzzle. Crit Care. 2010;14:165, doi:
10.1186/cc9035.
12. Zhan RZ, Fujiwara N, Shimoji K. Regionally Different Elevation Of
Intracellular Free Calcium In Hippocampus Of Septic Rat Brain. Shock.
1996;6:293-7, doi: 10.1097/00024382-199610000-00012.
13. Pytel P, Alexander JJ. Pathogenesis Of Septic Encephalopathy. Curr Opin
Neurol. 2009;22:283-7, doi: 10.1097/WCO.0b013e32832b3101.
14. Han L, Mccusker J, Cole M, Abrahamowicz M, Primeau F, Elie M. Use Of
Medications With Anticholinergic Effect Predicts Clinical Severity Of
Delirium Symptoms In Older Medical Inpatients. Arch Intern Med.
2001;161:1099-105, doi: 10.1001/archinte.161.8.1099.
15. Kadoi Y, Saito S. An Alteration In The Gamma-Aminobutyric Acid
Receptor System In Experimentally Induced Septic Shock In Rats. Crit
Care Med 1996; 24 2:298-305, doi: 10.1097/00003246-199602000-00020.
16. Gunther ML, Morandi A, Ely EW. Pathophysiology Of Delirium In The
Intensive Care Unit. Crit Care Clin. 2008;24:45-65, doi: 10.1016/j.ccc.2007.
10.002.
17. Comim CM, Pereira JG, Steckert A, Petronilho F, Barichello T, Quevedo J,
et al. Rivastigmine Reverses Habituation Memory Impairment Observed
In Sepsis Survivor Rats. Shock. 2009;32:270-1, doi: 10.1097/SHK.
0b013e31819963c4.
18. Pandharipande PP, Morandi A, Adams JR, Girard TD, Thompson JL,
Shintani AK, et al. Plasma Tryptophan And Tyrosine Levels Are
Independent Risk Factors For Delirium In Critically Ill Patients.
Intensive Care Med. 2009;35:1886-92, doi: 10.1007/s00134-009-1573-6.
19. James JH. Branched Chain Amino Acids In Heptatic Encephalopathy.
Am J Surg. 2002;183:424-9, doi: 10.1016/S0002-9610(02)00808-5.
20. Berg RM, Taudorf S, Bailey DM, Lundby C, Larsen FS, Pedersen BK, et al.
Cerebral Net Exchange Of Large Neutral Amino Acids After
Lipopolysaccharide Infusion In Healthy Humans. Crit Care.
2010;14:R16, doi: 10.1186/cc8873.
21. Mizock BA, Sabelli HC, Dubin A, Javaid JI, Poulos A, Rackow EC. Septic
Encephalopathy. Evidence For Altered Phenylalanine Metabolism And
Comparison With Hepatic Encephalopathy. Arch Intern Med.
1990;150:443-9, doi: 10.1001/archinte.150.2.443.
22. Freund HR, Ryan JA, Jr., Fischer JE. Amino Acid Derangements In
Patients With Sepsis: Treatment With Branched Chain Amino Acid Rich
Infusions. Ann Surg. 1978;188:423-30, doi: 10.1097/00000658-197809000-
00017.
23. Azevedo LC. Mitochondrial Dysfunction During Sepsis. Endocr Metab
Immune Disord Drug Targets. 2010;10:214-23.
24. Levy RJ. Mitochondrial Dysfunction, Bioenergetic Impairment, And
Metabolic Down-Regulation In Sepsis. Shock. 2007;28:24-8, doi: 10.1097/
01.shk.0000235089.30550.2d.
25. Hubbard WJ, Bland KI, Chaudry IH. The Role Of The Mitochondrion
In Trauma And Shock. Shock. 2004;22:395-402, doi: 10.1097/01.shk.
0000143407.90473.cc.
26. HotchkissRS,Swanson PE,Freeman BD,TinsleyKW,CobbJP,Matuschak
GM, et al. Apoptotic Cell Death In Patients With Sepsis, Shock, And
Multiple Organ Dysfunction. Crit Care Med. 1999;27:1230-51, doi: 10.
1097/00003246-199907000-00002.
27. Fink MP. Administration Of Exogenous Cytochrome C As A Novel
Approach For The Treatment Of Cytopathic Hypoxia. Crit Care Med.
2007;35:2224-5, doi: 10.1097/01.CCM.0000281464.75703.AD.
28. d’Avila JC, Santiago AP, Amancio RT, Galina A, Oliveira MF, Bozza FA.
Sepsis Induces Brain Mitochondrial Dysfunction. Crit Care Med.
2008;36:1925-32, doi: 10.1097/CCM.0b013e3181760c4b.
29. Messaris E, Memos N, Chatzigianni E, Konstadoulakis MM, Menenakos
E, Katsaragakis S, et al. Time-Dependent Mitochondrial-Mediated
Programmed Neuronal Cell Death Prolongs Survival In Sepsis. Crit
Care Med. 2004;32:1764-70, doi: 10.1097/01.CCM.0000135744.30137.B4.
30. Papadopoulos MC, Davies DC, Moss RF, Tighe D, Bennett ED.
Pathophysiology Of Septic Encephalopathy: A Review. Crit Care Med.
2000;28:3019-24, doi: 10.1097/00003246-200008000-00057.
31. Hopkins RO, Jackson JC. Long-Term Neurocognitive Function After
Critical Illness. Chest. 2006;130:869-78, doi: 10.1378/chest.130.3.869.
32. Iwashyna TJ, Ely EW, Smith DM, Langa KM. Long-Term Cognitive
Impairment And Functional Disability Among Survivors Of Severe
Sepsis. JAMA. 2010;304:1787-94, doi: 10.1001/jama.2010.1553.
33. Semmler A, Frisch C, Debeir T, Ramanathan M, Okulla T, Klockgether T,
et al. Long-Term Cognitive Impairment, Neuronal Loss And Reduced
Cortical Cholinergic Innervation After Recovery From Sepsis In A Rodent
Model. Exp Neurol. 2007;204:733-40, doi: 10.1016/j.expneurol.2007.01.003.
34. Hsu AA, Fenton K, Weinstein S, Carpenter J, Dalton H, Bell MJ.
Neurological Injury Markers In Children With Septic Shock. Pediatr Crit
Care Med. 2008;9:245-51, doi: 10.1097/PCC.0b013e3181727b22.
35. Vos PE, Verbeek MM. Brain Specific Proteins In Serum: Do They Reliably
Reflect Brain Damage? Shock. 2002;18:481-2, doi: 10.1097/00024382-
200211000-00017.
36. Routsi C, Stamataki E, Nanas S, Psachoulia C, Stathopoulos A, Koroneos
A, et al. Increased Levels Of Serum S100B Protein In Critically Ill Patients
Without Brain Injury. Shock. 2006;26:20-4, doi: 10.1097/01.shk.
0000209546.06801.d7.
37. Piazza O, Russo E, Cotena S, Esposito G, Tufano R. Elevated S100B
Levels Do Not Correlate With The Severity Of Encephalopathy During
Sepsis. Br J Anaesth. 2007;99:518-21, doi: 10.1093/bja/aem201.
38. Nishioku T, Dohgu S, Takata F, Eto T, Ishikawa N, Kodama KB, et al.
Detachment Of Brain Pericytes From The Basal Lamina Is Involved In
Disruption Of The Blood-Brain Barrier Caused By Lipopolysaccharide-
Induced Sepsis In Mice. Cell Mol Neurobiol. 2009;29:309-16, doi: 10.
1007/s10571-008-9322-x.
39. Handa O, Stephen J, Cepinskas G. Role Of Endothelial Nitric Oxide
Synthase-Derived Nitric Oxide In Activation And Dysfunction Of
Cerebrovascular Endothelial Cells During Early Onsets Of Sepsis.
Am J Physiol Heart Circ Physiol. 2008; 295:H1712-H1719, doi: 10.1152/
ajpheart.00476.2008.
40. Pan W, Yu C, Hsuchou H, Zhang Y, Kastin AJ. Neuroinflammation
Facilitates LIF Entry Into Brain: Role Of TNF. Am J Physiol Cell Physiol.
2008;294:C1436-C1442, doi: 10.1152/ajpcell.00489.2007.
41. Hofer S, Bopp C, Hoerner C, Plaschke K, Faden RM, Martin E, et al.
Injury Of The Blood Brain Barrier And Up-Regulation Of Icam-1 In
Polymicrobial Sepsis. J Surg Res. 2008;146:276-81.
42. Sharshar T, Carlier R, Bernard F, Guidoux C, Brouland JP, Nardi O, et al.
Brain Lesions In Septic Shock: A Magnetic Resonance Imaging Study.
Intensive Care Med. 2007;33:798-806, doi: 10.1007/s00134-007-0598-y.
Sepsis-associated encephalopathy
Zampieri FG et al.
CLINICS 2011;66(10):1825-1831
183043. Alexander JJ, Jacob A, Cunningham P, Hensley L, Quigg RJ. TNF Is A
Key Mediator Of Septic Encephalopathy Acting Through Its Receptor,
TNF Receptor-1. Neurochem Int. 2008;52:447-56, doi: 10.1016/j.neuint.
2007.08.006.
44. Jacob A, Hensley LK, Safratowich BD, Quigg RJ, Alexander JJ. The Role Of
The Complement Cascade In Endotoxin-Induced Septic Encephalopathy.
Lab Invest. 2007;87:1186-94, doi: 10.1038/labinvest.3700686.
45. Flierl MA, Stahel PF, Rittirsch D, Huber-Lang M, Niederbichler AD,
Hoesel LM, et al. Inhibition Of Complement C5a Prevents Breakdown Of
The Blood-Brain Barrier And Pituitary Dysfunction In Experimental
Sepsis. Crit Care. 2009;13:R12, doi: 10.1186/cc7710.
46. Sharshar T, Annane D, De La Grandmaison GL, Brouland JP, Hopkinson
NS, Francoise G. The Neuropathology Of Septic Shock. Brain Pathol.
2004;14:21-33, doi: 10.1111/j.1750-3639.2004.tb00494.x.
47. Burkhart CS, Siegemund M, Steiner LA. Cerebral Perfusion In Sepsis.
Crit Care. 2010;14:215, doi: 10.1186/cc8856.
48. Janz DR, Abel TW, Jackson JC, Gunther M, Heckers S, Ely EW. Brain
Autopsy Findings In Intensive Care Unit Patients Previously Suffering
From Delirium: A Pilot Study. J Crit Care. 2010;25:538.e7-12, doi: 10.1016/j.
jcrc.2010.05.004.
49. Bowton DL, Bertels NH, Prough DS, Stump DA. Cerebral Blood Flow Is
ReducedInPatientsWithSepsisSyndrome.CritCare Med.1989;17:399-403,
doi: 10.1097/00003246-198905000-00004.
50. Pfister D, Siegemund M, Dell-Kuster S, Smielewski P, Ruegg S, Strebel
SP, et al. Cerebral Perfusion In Sepsis-Associated Delirium. Crit Care.
2008;12:R63, doi: 10.1186/cc6891.
51. Taccone FS, Su F, Pierrakos C, He X, James S, Dewitte O, et al. Cerebral
Microcirculation Is Impaired During Sepsis: An Experimental Study. Crit
Care. 2010;14:R140, doi: 10.1186/cc9205.
52. Morandi A, Pandharipande P, Trabucchi M, Rozzini R, Mistraletti G,
Trompeo AC, et al. Understanding International Differences In
Terminology For Delirium And Other Types Of Acute Brain
Dysfunction In Critically Ill Patients. Intensive Care Med. 2008;
34:1907-15, doi: 10.1007/s00134-008-1177-6.
53. Siami S, Annane D, Sharshar T. The Encephalopathy In Sepsis. Crit Care
Clin. 2008;24:67-82, doi: 10.1016/j.ccc.2007.10.001.
54. Stevens RD, Pronovost PJ. The Spectrum Of Encephalopathy In Critical
Illness. Semin Neurol. 2006;26:440-51, doi: 10.1055/s-2006-948325.
55. Ely EW, Margolin R, Francis J, May L, Truman B, Dittus R, et al.
Evaluation Of Delirium In Critically Ill Patients: Validation Of The
Confusion Assessment Method For The Intensive Care Unit (CAM-ICU).
Crit Care Med. 2001;29:1370-9, doi: 10.1097/00003246-200107000-00012.
56. Bello JH, Park M. Sepsis-Associated Encephalopathy As A Differential
Diagnosis With Motor Deficit Plus Altered Mental Status. Clinics.
2007;62:199-202, doi: 10.1590/S1807-59322007000200017.
57. Abe S, Okumura A, Fujii T, Someya T, Tadokoro R, Arai Y, et al. Sepsis
Associated Encephalopathy In An Infant With Biliary Atresia. Brain Dev.
2008;30:544-7, doi: 10.1016/j.braindev.2007.12.015.
58. Young GB, Bolton CF, Archibald YM, Austin TW, Wells GA. The
Electroencephalogram In Sepsis-Associated Encephalopathy. J Clin
Neurophysiol. 1992;9:145-52, doi: 10.1097/00004691-199201000-00016.
59. Young GB, Bolton CF, Austin TW, Archibald YM, Gonder J, Wells GA.
The Encephalopathy Associated With Septic Illness. Clin Invest Med.
1990;13:297-304.
60. Suchyta MR, Jephson A, Hopkins RO. Neurologic Changes During
Critical Illness: Brain Imaging Findings And Neurobehavioral Outcomes.
Brain Imaging Behav. 2010;4:22-34, doi: 10.1007/s11682-009-9082-3.
61. Hopkins RO, Gale SD, Weaver LK. Brain Atrophy And Cognitive
Impairment In Survivors Of Acute Respiratory Distress Syndrome. Brain
Inj. 2006;20:263-71, doi: 10.1080/02699050500488199.
62. Bartynski WS, Boardman JF, Zeigler ZR, Shadduck RK, Lister J. Posterior
Reversible Encephalopathy Syndrome In Infection, Sepsis, And Shock.
AJNR Am J Neuroradiol. 2006;27:2179-90.
63. Guo RF, Riedemann NC, Ward PA. Role Of C5a-C5ar Interaction In
Sepsis. Shock. 2004;21:1-7, doi: 10.1097/01.shk.0000105502.75189.5e.
64. Spapen H, Nguyen DN, Troubleyn J, Huyghens L, Schiettecatte J.
Drotrecogin Alfa (Activated) May Attenuate Severe Sepsis-Associated
Encephalopathy In Clinical Septic Shock. Crit Care. 2010;14:R54, doi: 10.
1186/cc8947.
65. Pandharipande PP, Pun BT, Herr DL, Maze M, Girard TD, Miller RR,
et al. Effect Of Sedation With Dexmedetomidine Vs Lorazepam On
Acute Brain Dysfunction In Mechanically Ventilated Patients: The
MENDS Randomized Controlled Trial. JAMA. 2007;298:2644-53, doi:
10.1001/jama.298.22.2644.
66. Pandharipande PP, Sanders RD, Girard TD, Mcgrane S, Thompson JL,
Shintani AK, et al. Effect Of Dexmedetomidine Versus Lorazepam On
Outcome In Patients With Sepsis: An A Priori-Designed Analysis Of The
MENDSRandomizedControlledTrial.CritCare. 2010;14:R38,doi:10.1186/
cc8916.
67. Ma D, Hossain M, Rajakumaraswamy N, Arshad M, Sanders RD, Franks
NP, et al. Dexmedetomidine Produces Its Neuroprotective Effect Via The
Alpha 2A-Adrenoceptor Subtype. Eur J Pharmacol. 2004;502:87-97, doi:
10.1016/j.ejphar.2004.08.044.
CLINICS 2011;66(10):1825-1831 Sepsis-associated encephalopathy
Zampieri FG et al.
1831